ReviewCureus2025
Evolving Strategies in Amblyopia Management: From Traditional Therapies to Cutting-Edge Innovations.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amblyopia, commonly referred to as "lazy eye," is a prevalent visual disorder affecting children and, in some cases, adults. Traditional treatments, including occlusion therapy and pharmacological approaches, have demonstrated efficacy but also face limitations related to adherence, age dependency, and recurrence rates. This narrative review explores evolving strategies in amblyopia management, from conventional therapies to emerging innovations. Dichoptic therapy, which leverages binocular visual stimulation, represents a paradigm shift by directly addressing neural suppression and improving stereopsis. Technological advancements, such as virtual reality (VR), AI, and eye-tracking technologies, have further revolutionized treatment approaches, enhancing compliance and enabling personalized care. Additionally, recent research in neuroplasticity has opened new avenues for treating adult amblyopia, challenging previous assumptions about its irreversibility. Despite these advancements, challenges persist in treatment standardization, accessibility, and long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.